Last reviewed · How we verify

NCT06735885

fMRI Neurofeedback With Matter Neuroscience App

Recruiting now NA Last updated 17 December 2025
What this trial tests

NA trial testing Matter Neuroscience App in Depression Mild in 240 participants. Currently enrolling.

Timeline
12 August 2025
Primary endpoint
15 June 2027
15 June 2028

Quick facts

Lead sponsorStanford University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment240
Start date12 August 2025
Primary completion15 June 2027
Estimated completion15 June 2028
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Stanford University

Who can join

Adults 18 to 80, any sex, with Depression Mild or Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study will utilize an app, Matter Neuroscience, designed to help users with depression understand positive emotions and the neurotransmitters that create them. We hope to learn the safety and efficacy of neurofeedback for treating depression and lay the groundwork for a pivotal clinical trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Depression Mild

Currently open trials in the same condition.

Other Stanford University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06735885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing